Skip to content

Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke Clinic

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01109875
Enrollment
1000
Registered
2010-04-23
Start date
2010-05-31
Completion date
Unknown
Last updated
2014-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease in the Young Stroke

Brief summary

The purpose of this study is to determine the incidence of Fabry Disease in young stroke patients in an Israeli stroke clinic.

Interventions

OTHERblood test

Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).

Sponsors

Wolfson Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

diagnosis of stoke or TIA Time period within last 5 years -

Exclusion criteria

Known diagnosis of stroke or index event due to trauma \-

Design outcomes

Primary

MeasureTime frame
positive screening of fabry diseasepast 5 years

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026